FDA approves Lupin's generic Latuda
The Food and Drug Administration has greenlighted Lupin’s generic Latuda (lurasidone hydrochloride) tablets. They will be available in 20-mg, 40-mg, 60-mg, 80-mg and 120-mg dosage strengths.
The generic Latuda is indicated for the treatment of adult patients with schizophrenia; monotherapy treatment of adult patients with major depressive episode associated with bipolar I disorder (bipolar depression); and adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder.
Latuda tablets had a market value of approximately $3.2 billion, according to September 2018 data.
The generic Latuda is indicated for the treatment of adult patients with schizophrenia; monotherapy treatment of adult patients with major depressive episode associated with bipolar I disorder (bipolar depression); and adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder.
Latuda tablets had a market value of approximately $3.2 billion, according to September 2018 data.